This stock appears to be well undervalued at 2.5c and could well justify a SP of 20c should it gain traction in the EU markets...however one should remember that it is completely out of cash at the moment having to rely on its major shareholder to finance the company via a Convertible Note facility
ovarian cancer
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
